Codexis, Inc. (CDXS)
- GlobeNewswire
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an increase in its cash reserves through capital raises totaling $31 million via the Company’s exi
- GlobeNewswire
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences
Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applicationsREDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC, part of Maravai LifeSciences, for multiple enzymes in Codexis’ life science enzyme portfo
- GuruFocus.com
Opaleye Management Inc. Increases Stake in Codexis Inc.
On September 18, 2024, Opaleye Management Inc. (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 4,130,000 shares of Codexis Inc. (NASDAQ:CDXS), a prominent player in the enzyme optimization sector. This transaction not only increased the firm's total holdings in Codexis to 7,585,000 shares but also elevated its portfolio position to 5.41%, reflecting a substantial commitment to this biotechnology entity. Based in Cambridge, MA, Opaleye Management Inc. (Trades, Portfolio) is a focused investment firm with a keen interest in the healthcare sector, particularly biotechnology and pharmaceuticals.
